Global Infectious Vaccines Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Infectious Vaccines market size was valued at US$ million in 2023. With growing demand in downstream market, the Infectious Vaccines is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Infectious Vaccines market. Infectious Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Infectious Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Infectious Vaccines market.
A vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease which help to improve the immunity of the target body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Infectious Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Infectious Vaccines market. It may include historical data, market segmentation by Type (e.g., Preventive Vaccine, Therapeutic Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Infectious Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Infectious Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Infectious Vaccines industry. This include advancements in Infectious Vaccines technology, Infectious Vaccines new entrants, Infectious Vaccines new investment, and other innovations that are shaping the future of Infectious Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Infectious Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for Infectious Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Infectious Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Infectious Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Infectious Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Infectious Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Infectious Vaccines market.
Market Segmentation:
Infectious Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Infectious Vaccines market?
What factors are driving Infectious Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Infectious Vaccines market opportunities vary by end market size?
How does Infectious Vaccines break out type, application?
According to our LPI (LP Information) latest study, the global Infectious Vaccines market size was valued at US$ million in 2023. With growing demand in downstream market, the Infectious Vaccines is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Infectious Vaccines market. Infectious Vaccines are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Infectious Vaccines. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Infectious Vaccines market.
A vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease which help to improve the immunity of the target body.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Infectious Vaccines market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Infectious Vaccines market. It may include historical data, market segmentation by Type (e.g., Preventive Vaccine, Therapeutic Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Infectious Vaccines market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Infectious Vaccines market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Infectious Vaccines industry. This include advancements in Infectious Vaccines technology, Infectious Vaccines new entrants, Infectious Vaccines new investment, and other innovations that are shaping the future of Infectious Vaccines.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Infectious Vaccines market. It includes factors influencing customer ' purchasing decisions, preferences for Infectious Vaccines product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Infectious Vaccines market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Infectious Vaccines market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Infectious Vaccines market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Infectious Vaccines industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Infectious Vaccines market.
Market Segmentation:
Infectious Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Preventive Vaccine
- Therapeutic Vaccine
- Adults
- Pediatrics
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- CSL Limited (Australia)
- Bavarian Nordic (Denmark)
- GlaxoSmithKline plc. (U.K.)
- Emergent Bio Solutions Inc. (U.S.)
- MedImmune LLC (U.S.)
- Johnson and Johnson (U.S.)
- Novartis AG (Switzerland)
- Merck and Company (U.S.)
- Sanofi Pasteur (France)
- Pfizer Inc. (U.S.)
What is the 10-year outlook for the global Infectious Vaccines market?
What factors are driving Infectious Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Infectious Vaccines market opportunities vary by end market size?
How does Infectious Vaccines break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Infectious Vaccines Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Infectious Vaccines by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Infectious Vaccines by Country/Region, 2019, 2023 & 2030
2.2 Infectious Vaccines Segment by Type
2.2.1 Preventive Vaccine
2.2.2 Therapeutic Vaccine
2.3 Infectious Vaccines Sales by Type
2.3.1 Global Infectious Vaccines Sales Market Share by Type (2019-2024)
2.3.2 Global Infectious Vaccines Revenue and Market Share by Type (2019-2024)
2.3.3 Global Infectious Vaccines Sale Price by Type (2019-2024)
2.4 Infectious Vaccines Segment by Application
2.4.1 Adults
2.4.2 Pediatrics
2.5 Infectious Vaccines Sales by Application
2.5.1 Global Infectious Vaccines Sale Market Share by Application (2019-2024)
2.5.2 Global Infectious Vaccines Revenue and Market Share by Application (2019-2024)
2.5.3 Global Infectious Vaccines Sale Price by Application (2019-2024)
3 GLOBAL INFECTIOUS VACCINES BY COMPANY
3.1 Global Infectious Vaccines Breakdown Data by Company
3.1.1 Global Infectious Vaccines Annual Sales by Company (2019-2024)
3.1.2 Global Infectious Vaccines Sales Market Share by Company (2019-2024)
3.2 Global Infectious Vaccines Annual Revenue by Company (2019-2024)
3.2.1 Global Infectious Vaccines Revenue by Company (2019-2024)
3.2.2 Global Infectious Vaccines Revenue Market Share by Company (2019-2024)
3.3 Global Infectious Vaccines Sale Price by Company
3.4 Key Manufacturers Infectious Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Infectious Vaccines Product Location Distribution
3.4.2 Players Infectious Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INFECTIOUS VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Infectious Vaccines Market Size by Geographic Region (2019-2024)
4.1.1 Global Infectious Vaccines Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Infectious Vaccines Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Infectious Vaccines Market Size by Country/Region (2019-2024)
4.2.1 Global Infectious Vaccines Annual Sales by Country/Region (2019-2024)
4.2.2 Global Infectious Vaccines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Infectious Vaccines Sales Growth
4.4 APAC Infectious Vaccines Sales Growth
4.5 Europe Infectious Vaccines Sales Growth
4.6 Middle East & Africa Infectious Vaccines Sales Growth
5 AMERICAS
5.1 Americas Infectious Vaccines Sales by Country
5.1.1 Americas Infectious Vaccines Sales by Country (2019-2024)
5.1.2 Americas Infectious Vaccines Revenue by Country (2019-2024)
5.2 Americas Infectious Vaccines Sales by Type
5.3 Americas Infectious Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infectious Vaccines Sales by Region
6.1.1 APAC Infectious Vaccines Sales by Region (2019-2024)
6.1.2 APAC Infectious Vaccines Revenue by Region (2019-2024)
6.2 APAC Infectious Vaccines Sales by Type
6.3 APAC Infectious Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Infectious Vaccines by Country
7.1.1 Europe Infectious Vaccines Sales by Country (2019-2024)
7.1.2 Europe Infectious Vaccines Revenue by Country (2019-2024)
7.2 Europe Infectious Vaccines Sales by Type
7.3 Europe Infectious Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Infectious Vaccines by Country
8.1.1 Middle East & Africa Infectious Vaccines Sales by Country (2019-2024)
8.1.2 Middle East & Africa Infectious Vaccines Revenue by Country (2019-2024)
8.2 Middle East & Africa Infectious Vaccines Sales by Type
8.3 Middle East & Africa Infectious Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Infectious Vaccines
10.3 Manufacturing Process Analysis of Infectious Vaccines
10.4 Industry Chain Structure of Infectious Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Infectious Vaccines Distributors
11.3 Infectious Vaccines Customer
12 WORLD FORECAST REVIEW FOR INFECTIOUS VACCINES BY GEOGRAPHIC REGION
12.1 Global Infectious Vaccines Market Size Forecast by Region
12.1.1 Global Infectious Vaccines Forecast by Region (2025-2030)
12.1.2 Global Infectious Vaccines Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Infectious Vaccines Forecast by Type
12.7 Global Infectious Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CSL Limited (Australia)
13.1.1 CSL Limited (Australia) Company Information
13.1.2 CSL Limited (Australia) Infectious Vaccines Product Portfolios and Specifications
13.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 CSL Limited (Australia) Main Business Overview
13.1.5 CSL Limited (Australia) Latest Developments
13.2 Bavarian Nordic (Denmark)
13.2.1 Bavarian Nordic (Denmark) Company Information
13.2.2 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolios and Specifications
13.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bavarian Nordic (Denmark) Main Business Overview
13.2.5 Bavarian Nordic (Denmark) Latest Developments
13.3 GlaxoSmithKline plc. (U.K.)
13.3.1 GlaxoSmithKline plc. (U.K.) Company Information
13.3.2 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GlaxoSmithKline plc. (U.K.) Main Business Overview
13.3.5 GlaxoSmithKline plc. (U.K.) Latest Developments
13.4 Emergent Bio Solutions Inc. (U.S.)
13.4.1 Emergent Bio Solutions Inc. (U.S.) Company Information
13.4.2 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Emergent Bio Solutions Inc. (U.S.) Main Business Overview
13.4.5 Emergent Bio Solutions Inc. (U.S.) Latest Developments
13.5 MedImmune LLC (U.S.)
13.5.1 MedImmune LLC (U.S.) Company Information
13.5.2 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 MedImmune LLC (U.S.) Main Business Overview
13.5.5 MedImmune LLC (U.S.) Latest Developments
13.6 Johnson and Johnson (U.S.)
13.6.1 Johnson and Johnson (U.S.) Company Information
13.6.2 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson and Johnson (U.S.) Main Business Overview
13.6.5 Johnson and Johnson (U.S.) Latest Developments
13.7 Novartis AG (Switzerland)
13.7.1 Novartis AG (Switzerland) Company Information
13.7.2 Novartis AG (Switzerland) Infectious Vaccines Product Portfolios and Specifications
13.7.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Novartis AG (Switzerland) Main Business Overview
13.7.5 Novartis AG (Switzerland) Latest Developments
13.8 Merck and Company (U.S.)
13.8.1 Merck and Company (U.S.) Company Information
13.8.2 Merck and Company (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Merck and Company (U.S.) Main Business Overview
13.8.5 Merck and Company (U.S.) Latest Developments
13.9 Sanofi Pasteur (France)
13.9.1 Sanofi Pasteur (France) Company Information
13.9.2 Sanofi Pasteur (France) Infectious Vaccines Product Portfolios and Specifications
13.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sanofi Pasteur (France) Main Business Overview
13.9.5 Sanofi Pasteur (France) Latest Developments
13.10 Pfizer Inc. (U.S.)
13.10.1 Pfizer Inc. (U.S.) Company Information
13.10.2 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer Inc. (U.S.) Main Business Overview
13.10.5 Pfizer Inc. (U.S.) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Infectious Vaccines Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Infectious Vaccines by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Infectious Vaccines by Country/Region, 2019, 2023 & 2030
2.2 Infectious Vaccines Segment by Type
2.2.1 Preventive Vaccine
2.2.2 Therapeutic Vaccine
2.3 Infectious Vaccines Sales by Type
2.3.1 Global Infectious Vaccines Sales Market Share by Type (2019-2024)
2.3.2 Global Infectious Vaccines Revenue and Market Share by Type (2019-2024)
2.3.3 Global Infectious Vaccines Sale Price by Type (2019-2024)
2.4 Infectious Vaccines Segment by Application
2.4.1 Adults
2.4.2 Pediatrics
2.5 Infectious Vaccines Sales by Application
2.5.1 Global Infectious Vaccines Sale Market Share by Application (2019-2024)
2.5.2 Global Infectious Vaccines Revenue and Market Share by Application (2019-2024)
2.5.3 Global Infectious Vaccines Sale Price by Application (2019-2024)
3 GLOBAL INFECTIOUS VACCINES BY COMPANY
3.1 Global Infectious Vaccines Breakdown Data by Company
3.1.1 Global Infectious Vaccines Annual Sales by Company (2019-2024)
3.1.2 Global Infectious Vaccines Sales Market Share by Company (2019-2024)
3.2 Global Infectious Vaccines Annual Revenue by Company (2019-2024)
3.2.1 Global Infectious Vaccines Revenue by Company (2019-2024)
3.2.2 Global Infectious Vaccines Revenue Market Share by Company (2019-2024)
3.3 Global Infectious Vaccines Sale Price by Company
3.4 Key Manufacturers Infectious Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Infectious Vaccines Product Location Distribution
3.4.2 Players Infectious Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INFECTIOUS VACCINES BY GEOGRAPHIC REGION
4.1 World Historic Infectious Vaccines Market Size by Geographic Region (2019-2024)
4.1.1 Global Infectious Vaccines Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Infectious Vaccines Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Infectious Vaccines Market Size by Country/Region (2019-2024)
4.2.1 Global Infectious Vaccines Annual Sales by Country/Region (2019-2024)
4.2.2 Global Infectious Vaccines Annual Revenue by Country/Region (2019-2024)
4.3 Americas Infectious Vaccines Sales Growth
4.4 APAC Infectious Vaccines Sales Growth
4.5 Europe Infectious Vaccines Sales Growth
4.6 Middle East & Africa Infectious Vaccines Sales Growth
5 AMERICAS
5.1 Americas Infectious Vaccines Sales by Country
5.1.1 Americas Infectious Vaccines Sales by Country (2019-2024)
5.1.2 Americas Infectious Vaccines Revenue by Country (2019-2024)
5.2 Americas Infectious Vaccines Sales by Type
5.3 Americas Infectious Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Infectious Vaccines Sales by Region
6.1.1 APAC Infectious Vaccines Sales by Region (2019-2024)
6.1.2 APAC Infectious Vaccines Revenue by Region (2019-2024)
6.2 APAC Infectious Vaccines Sales by Type
6.3 APAC Infectious Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Infectious Vaccines by Country
7.1.1 Europe Infectious Vaccines Sales by Country (2019-2024)
7.1.2 Europe Infectious Vaccines Revenue by Country (2019-2024)
7.2 Europe Infectious Vaccines Sales by Type
7.3 Europe Infectious Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Infectious Vaccines by Country
8.1.1 Middle East & Africa Infectious Vaccines Sales by Country (2019-2024)
8.1.2 Middle East & Africa Infectious Vaccines Revenue by Country (2019-2024)
8.2 Middle East & Africa Infectious Vaccines Sales by Type
8.3 Middle East & Africa Infectious Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Infectious Vaccines
10.3 Manufacturing Process Analysis of Infectious Vaccines
10.4 Industry Chain Structure of Infectious Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Infectious Vaccines Distributors
11.3 Infectious Vaccines Customer
12 WORLD FORECAST REVIEW FOR INFECTIOUS VACCINES BY GEOGRAPHIC REGION
12.1 Global Infectious Vaccines Market Size Forecast by Region
12.1.1 Global Infectious Vaccines Forecast by Region (2025-2030)
12.1.2 Global Infectious Vaccines Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Infectious Vaccines Forecast by Type
12.7 Global Infectious Vaccines Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CSL Limited (Australia)
13.1.1 CSL Limited (Australia) Company Information
13.1.2 CSL Limited (Australia) Infectious Vaccines Product Portfolios and Specifications
13.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 CSL Limited (Australia) Main Business Overview
13.1.5 CSL Limited (Australia) Latest Developments
13.2 Bavarian Nordic (Denmark)
13.2.1 Bavarian Nordic (Denmark) Company Information
13.2.2 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolios and Specifications
13.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bavarian Nordic (Denmark) Main Business Overview
13.2.5 Bavarian Nordic (Denmark) Latest Developments
13.3 GlaxoSmithKline plc. (U.K.)
13.3.1 GlaxoSmithKline plc. (U.K.) Company Information
13.3.2 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GlaxoSmithKline plc. (U.K.) Main Business Overview
13.3.5 GlaxoSmithKline plc. (U.K.) Latest Developments
13.4 Emergent Bio Solutions Inc. (U.S.)
13.4.1 Emergent Bio Solutions Inc. (U.S.) Company Information
13.4.2 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Emergent Bio Solutions Inc. (U.S.) Main Business Overview
13.4.5 Emergent Bio Solutions Inc. (U.S.) Latest Developments
13.5 MedImmune LLC (U.S.)
13.5.1 MedImmune LLC (U.S.) Company Information
13.5.2 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 MedImmune LLC (U.S.) Main Business Overview
13.5.5 MedImmune LLC (U.S.) Latest Developments
13.6 Johnson and Johnson (U.S.)
13.6.1 Johnson and Johnson (U.S.) Company Information
13.6.2 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson and Johnson (U.S.) Main Business Overview
13.6.5 Johnson and Johnson (U.S.) Latest Developments
13.7 Novartis AG (Switzerland)
13.7.1 Novartis AG (Switzerland) Company Information
13.7.2 Novartis AG (Switzerland) Infectious Vaccines Product Portfolios and Specifications
13.7.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Novartis AG (Switzerland) Main Business Overview
13.7.5 Novartis AG (Switzerland) Latest Developments
13.8 Merck and Company (U.S.)
13.8.1 Merck and Company (U.S.) Company Information
13.8.2 Merck and Company (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Merck and Company (U.S.) Main Business Overview
13.8.5 Merck and Company (U.S.) Latest Developments
13.9 Sanofi Pasteur (France)
13.9.1 Sanofi Pasteur (France) Company Information
13.9.2 Sanofi Pasteur (France) Infectious Vaccines Product Portfolios and Specifications
13.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sanofi Pasteur (France) Main Business Overview
13.9.5 Sanofi Pasteur (France) Latest Developments
13.10 Pfizer Inc. (U.S.)
13.10.1 Pfizer Inc. (U.S.) Company Information
13.10.2 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
13.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Pfizer Inc. (U.S.) Main Business Overview
13.10.5 Pfizer Inc. (U.S.) Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Infectious Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Infectious Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Preventive Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 6. Global Infectious Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Infectious Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Infectious Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Infectious Vaccines Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 11. Global Infectious Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Infectious Vaccines Revenue by Application (2019-2024)
Table 13. Global Infectious Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Infectious Vaccines Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Infectious Vaccines Sales by Company (2019-2024) & (K Units)
Table 16. Global Infectious Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Infectious Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Infectious Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Infectious Vaccines Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Infectious Vaccines Producing Area Distribution and Sales Area
Table 21. Players Infectious Vaccines Products Offered
Table 22. Infectious Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Infectious Vaccines Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Infectious Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Infectious Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Infectious Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Infectious Vaccines Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Infectious Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Infectious Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Infectious Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 34. Americas Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 38. Americas Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 39. APAC Infectious Vaccines Sales by Region (2019-2024) & (K Units)
Table 40. APAC Infectious Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Infectious Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Infectious Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 44. APAC Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 45. Europe Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 46. Europe Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 50. Europe Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Infectious Vaccines
Table 58. Key Market Challenges & Risks of Infectious Vaccines
Table 59. Key Industry Trends of Infectious Vaccines
Table 60. Infectious Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Infectious Vaccines Distributors List
Table 63. Infectious Vaccines Customer List
Table 64. Global Infectious Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Infectious Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Infectious Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Infectious Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Infectious Vaccines Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Infectious Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Infectious Vaccines Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Infectious Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. CSL Limited (Australia) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. CSL Limited (Australia) Infectious Vaccines Product Portfolios and Specifications
Table 80. CSL Limited (Australia) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. CSL Limited (Australia) Main Business
Table 82. CSL Limited (Australia) Latest Developments
Table 83. Bavarian Nordic (Denmark) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolios and Specifications
Table 85. Bavarian Nordic (Denmark) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Bavarian Nordic (Denmark) Main Business
Table 87. Bavarian Nordic (Denmark) Latest Developments
Table 88. GlaxoSmithKline plc. (U.K.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolios and Specifications
Table 90. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. GlaxoSmithKline plc. (U.K.) Main Business
Table 92. GlaxoSmithKline plc. (U.K.) Latest Developments
Table 93. Emergent Bio Solutions Inc. (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 95. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Emergent Bio Solutions Inc. (U.S.) Main Business
Table 97. Emergent Bio Solutions Inc. (U.S.) Latest Developments
Table 98. MedImmune LLC (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 100. MedImmune LLC (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. MedImmune LLC (U.S.) Main Business
Table 102. MedImmune LLC (U.S.) Latest Developments
Table 103. Johnson and Johnson (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 105. Johnson and Johnson (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Johnson and Johnson (U.S.) Main Business
Table 107. Johnson and Johnson (U.S.) Latest Developments
Table 108. Novartis AG (Switzerland) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Novartis AG (Switzerland) Infectious Vaccines Product Portfolios and Specifications
Table 110. Novartis AG (Switzerland) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Novartis AG (Switzerland) Main Business
Table 112. Novartis AG (Switzerland) Latest Developments
Table 113. Merck and Company (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck and Company (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 115. Merck and Company (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Merck and Company (U.S.) Main Business
Table 117. Merck and Company (U.S.) Latest Developments
Table 118. Sanofi Pasteur (France) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Sanofi Pasteur (France) Infectious Vaccines Product Portfolios and Specifications
Table 120. Sanofi Pasteur (France) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Sanofi Pasteur (France) Main Business
Table 122. Sanofi Pasteur (France) Latest Developments
Table 123. Pfizer Inc. (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 125. Pfizer Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. Pfizer Inc. (U.S.) Main Business
Table 127. Pfizer Inc. (U.S.) Latest Developments
Table 1. Infectious Vaccines Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Infectious Vaccines Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Preventive Vaccine
Table 4. Major Players of Therapeutic Vaccine
Table 5. Global Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 6. Global Infectious Vaccines Sales Market Share by Type (2019-2024)
Table 7. Global Infectious Vaccines Revenue by Type (2019-2024) & ($ million)
Table 8. Global Infectious Vaccines Revenue Market Share by Type (2019-2024)
Table 9. Global Infectious Vaccines Sale Price by Type (2019-2024) & (USD/Unit)
Table 10. Global Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 11. Global Infectious Vaccines Sales Market Share by Application (2019-2024)
Table 12. Global Infectious Vaccines Revenue by Application (2019-2024)
Table 13. Global Infectious Vaccines Revenue Market Share by Application (2019-2024)
Table 14. Global Infectious Vaccines Sale Price by Application (2019-2024) & (USD/Unit)
Table 15. Global Infectious Vaccines Sales by Company (2019-2024) & (K Units)
Table 16. Global Infectious Vaccines Sales Market Share by Company (2019-2024)
Table 17. Global Infectious Vaccines Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Infectious Vaccines Revenue Market Share by Company (2019-2024)
Table 19. Global Infectious Vaccines Sale Price by Company (2019-2024) & (USD/Unit)
Table 20. Key Manufacturers Infectious Vaccines Producing Area Distribution and Sales Area
Table 21. Players Infectious Vaccines Products Offered
Table 22. Infectious Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Infectious Vaccines Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Infectious Vaccines Sales Market Share Geographic Region (2019-2024)
Table 27. Global Infectious Vaccines Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Infectious Vaccines Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Infectious Vaccines Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Infectious Vaccines Sales Market Share by Country/Region (2019-2024)
Table 31. Global Infectious Vaccines Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Infectious Vaccines Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 34. Americas Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 35. Americas Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 37. Americas Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 38. Americas Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 39. APAC Infectious Vaccines Sales by Region (2019-2024) & (K Units)
Table 40. APAC Infectious Vaccines Sales Market Share by Region (2019-2024)
Table 41. APAC Infectious Vaccines Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Infectious Vaccines Revenue Market Share by Region (2019-2024)
Table 43. APAC Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 44. APAC Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 45. Europe Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 46. Europe Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 47. Europe Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 49. Europe Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 50. Europe Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Infectious Vaccines Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Infectious Vaccines Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Infectious Vaccines Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Infectious Vaccines Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Infectious Vaccines Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Infectious Vaccines Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Infectious Vaccines
Table 58. Key Market Challenges & Risks of Infectious Vaccines
Table 59. Key Industry Trends of Infectious Vaccines
Table 60. Infectious Vaccines Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Infectious Vaccines Distributors List
Table 63. Infectious Vaccines Customer List
Table 64. Global Infectious Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Infectious Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Infectious Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Infectious Vaccines Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Infectious Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Infectious Vaccines Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Infectious Vaccines Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Infectious Vaccines Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Infectious Vaccines Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Infectious Vaccines Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. CSL Limited (Australia) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. CSL Limited (Australia) Infectious Vaccines Product Portfolios and Specifications
Table 80. CSL Limited (Australia) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 81. CSL Limited (Australia) Main Business
Table 82. CSL Limited (Australia) Latest Developments
Table 83. Bavarian Nordic (Denmark) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolios and Specifications
Table 85. Bavarian Nordic (Denmark) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 86. Bavarian Nordic (Denmark) Main Business
Table 87. Bavarian Nordic (Denmark) Latest Developments
Table 88. GlaxoSmithKline plc. (U.K.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolios and Specifications
Table 90. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 91. GlaxoSmithKline plc. (U.K.) Main Business
Table 92. GlaxoSmithKline plc. (U.K.) Latest Developments
Table 93. Emergent Bio Solutions Inc. (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 95. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 96. Emergent Bio Solutions Inc. (U.S.) Main Business
Table 97. Emergent Bio Solutions Inc. (U.S.) Latest Developments
Table 98. MedImmune LLC (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 100. MedImmune LLC (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 101. MedImmune LLC (U.S.) Main Business
Table 102. MedImmune LLC (U.S.) Latest Developments
Table 103. Johnson and Johnson (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 105. Johnson and Johnson (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 106. Johnson and Johnson (U.S.) Main Business
Table 107. Johnson and Johnson (U.S.) Latest Developments
Table 108. Novartis AG (Switzerland) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Novartis AG (Switzerland) Infectious Vaccines Product Portfolios and Specifications
Table 110. Novartis AG (Switzerland) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 111. Novartis AG (Switzerland) Main Business
Table 112. Novartis AG (Switzerland) Latest Developments
Table 113. Merck and Company (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck and Company (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 115. Merck and Company (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 116. Merck and Company (U.S.) Main Business
Table 117. Merck and Company (U.S.) Latest Developments
Table 118. Sanofi Pasteur (France) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Sanofi Pasteur (France) Infectious Vaccines Product Portfolios and Specifications
Table 120. Sanofi Pasteur (France) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 121. Sanofi Pasteur (France) Main Business
Table 122. Sanofi Pasteur (France) Latest Developments
Table 123. Pfizer Inc. (U.S.) Basic Information, Infectious Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolios and Specifications
Table 125. Pfizer Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 126. Pfizer Inc. (U.S.) Main Business
Table 127. Pfizer Inc. (U.S.) Latest Developments
LIST OF FIGURES
Figure 1. Picture of Infectious Vaccines
Figure 2. Infectious Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Infectious Vaccines Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Infectious Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Infectious Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Preventive Vaccine
Figure 10. Product Picture of Therapeutic Vaccine
Figure 11. Global Infectious Vaccines Sales Market Share by Type in 2023
Figure 12. Global Infectious Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Infectious Vaccines Consumed in Adults
Figure 14. Global Infectious Vaccines Market: Adults (2019-2024) & (K Units)
Figure 15. Infectious Vaccines Consumed in Pediatrics
Figure 16. Global Infectious Vaccines Market: Pediatrics (2019-2024) & (K Units)
Figure 17. Global Infectious Vaccines Sales Market Share by Application (2023)
Figure 18. Global Infectious Vaccines Revenue Market Share by Application in 2023
Figure 19. Infectious Vaccines Sales Market by Company in 2023 (K Units)
Figure 20. Global Infectious Vaccines Sales Market Share by Company in 2023
Figure 21. Infectious Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Infectious Vaccines Revenue Market Share by Company in 2023
Figure 23. Global Infectious Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Infectious Vaccines Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Infectious Vaccines Sales 2019-2024 (K Units)
Figure 26. Americas Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 27. APAC Infectious Vaccines Sales 2019-2024 (K Units)
Figure 28. APAC Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. Europe Infectious Vaccines Sales 2019-2024 (K Units)
Figure 30. Europe Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Infectious Vaccines Sales 2019-2024 (K Units)
Figure 32. Middle East & Africa Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Americas Infectious Vaccines Sales Market Share by Country in 2023
Figure 34. Americas Infectious Vaccines Revenue Market Share by Country in 2023
Figure 35. Americas Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 36. Americas Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 37. United States Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Infectious Vaccines Sales Market Share by Region in 2023
Figure 42. APAC Infectious Vaccines Revenue Market Share by Regions in 2023
Figure 43. APAC Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 44. APAC Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 45. China Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Infectious Vaccines Sales Market Share by Country in 2023
Figure 53. Europe Infectious Vaccines Revenue Market Share by Country in 2023
Figure 54. Europe Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 55. Europe Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 56. Germany Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Infectious Vaccines Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Infectious Vaccines Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 65. Egypt Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Infectious Vaccines in 2023
Figure 71. Manufacturing Process Analysis of Infectious Vaccines
Figure 72. Industry Chain Structure of Infectious Vaccines
Figure 73. Channels of Distribution
Figure 74. Global Infectious Vaccines Sales Market Forecast by Region (2025-2030)
Figure 75. Global Infectious Vaccines Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Infectious Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Infectious Vaccines Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Infectious Vaccines Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Infectious Vaccines Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Infectious Vaccines
Figure 2. Infectious Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Infectious Vaccines Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Infectious Vaccines Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Infectious Vaccines Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Preventive Vaccine
Figure 10. Product Picture of Therapeutic Vaccine
Figure 11. Global Infectious Vaccines Sales Market Share by Type in 2023
Figure 12. Global Infectious Vaccines Revenue Market Share by Type (2019-2024)
Figure 13. Infectious Vaccines Consumed in Adults
Figure 14. Global Infectious Vaccines Market: Adults (2019-2024) & (K Units)
Figure 15. Infectious Vaccines Consumed in Pediatrics
Figure 16. Global Infectious Vaccines Market: Pediatrics (2019-2024) & (K Units)
Figure 17. Global Infectious Vaccines Sales Market Share by Application (2023)
Figure 18. Global Infectious Vaccines Revenue Market Share by Application in 2023
Figure 19. Infectious Vaccines Sales Market by Company in 2023 (K Units)
Figure 20. Global Infectious Vaccines Sales Market Share by Company in 2023
Figure 21. Infectious Vaccines Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Infectious Vaccines Revenue Market Share by Company in 2023
Figure 23. Global Infectious Vaccines Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Infectious Vaccines Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Infectious Vaccines Sales 2019-2024 (K Units)
Figure 26. Americas Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 27. APAC Infectious Vaccines Sales 2019-2024 (K Units)
Figure 28. APAC Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 29. Europe Infectious Vaccines Sales 2019-2024 (K Units)
Figure 30. Europe Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Infectious Vaccines Sales 2019-2024 (K Units)
Figure 32. Middle East & Africa Infectious Vaccines Revenue 2019-2024 ($ Millions)
Figure 33. Americas Infectious Vaccines Sales Market Share by Country in 2023
Figure 34. Americas Infectious Vaccines Revenue Market Share by Country in 2023
Figure 35. Americas Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 36. Americas Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 37. United States Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Infectious Vaccines Sales Market Share by Region in 2023
Figure 42. APAC Infectious Vaccines Revenue Market Share by Regions in 2023
Figure 43. APAC Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 44. APAC Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 45. China Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Infectious Vaccines Sales Market Share by Country in 2023
Figure 53. Europe Infectious Vaccines Revenue Market Share by Country in 2023
Figure 54. Europe Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 55. Europe Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 56. Germany Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Infectious Vaccines Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Infectious Vaccines Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Infectious Vaccines Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Infectious Vaccines Sales Market Share by Application (2019-2024)
Figure 65. Egypt Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Infectious Vaccines Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Infectious Vaccines in 2023
Figure 71. Manufacturing Process Analysis of Infectious Vaccines
Figure 72. Industry Chain Structure of Infectious Vaccines
Figure 73. Channels of Distribution
Figure 74. Global Infectious Vaccines Sales Market Forecast by Region (2025-2030)
Figure 75. Global Infectious Vaccines Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Infectious Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Infectious Vaccines Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Infectious Vaccines Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Infectious Vaccines Revenue Market Share Forecast by Application (2025-2030)
